Hovione, a CDMO, is expanding its global manufacturing network with an investment cycle that includes an initial $100-million investment in the United States and additional capacity expansions across its European sites. David Basile, Vice President, Technical Operations, Americas, Hovione, outlined the company’s expansion plan at the DCAT Member Company Announcement Forum, held March 23, 2026, at DCAT Week.

The strategy is aimed at increasing regional proximity to customers and expanding access to specialized technologies for complex small-molecule medicines. A central element of the investment is the expansion of Hovione’s site in East Windsor, New Jersey, where the company has operated for more than 25 years. The project will further develop the site into an integrated campus that combines drug-substance development, scale-up, and drug-product manufacturing within a single quality and governance system at one location from development through commercial manufacturing

The expansion includes a new 31,000-square-foot facility at 89 Twin Rivers Drive that will house two Particle Spray Drying-3 (PSD-3) units for the production of amorphous solid dispersions. The units are scheduled to begin GMP operations in the coming weeks (as reported on March 23, 2026) and will operate alongside Hovione’s existing spray-drying infrastructure in New Jersey, including two PSD units commissioned in 2025.

The company reports continued demand for spray-drying technologies used to address solubility and bioavailability challenges in complex small molecules. Hovione also plans to introduce a continuous tableting line at the site in 2028 using GEA’s ConsiGma CDC Flex system. The platform will support continuous direct compression for potent products and allow operation in both continuous and batch modes.

As part of its US expansion, Hovione has also acquired adjacent land to support additional development at the New Jersey campus. Plans include a 125,000-square-foot greenfield facility designed to support larger-scale production, including continuous and batch tableting operations, along with expanded digital and quality-control infrastructure.

Beyond the US, the company is expanding its European manufacturing footprint as part of a broader global investment program. Construction is progressing at Hovione’s Tejo campus in Seixal, Portugal, a 4.5-million-square-foot development designed to support particle engineering and final-dosage-form production. The first phase of the $235-million project is expected to be completed by mid-2027 and includes sustainability initiatives aimed at reducing the company’s carbon footprint by 40% by 2030.

Additional investments have been made at Hovione’s Loures site in Portugal with the addition of a biotechnology unit and expanded spray-drying capacity. The company has also expanded its Ireland facility, nearly doubling spray-drying capacity at that site.